JP2017526695A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526695A5
JP2017526695A5 JP2017512679A JP2017512679A JP2017526695A5 JP 2017526695 A5 JP2017526695 A5 JP 2017526695A5 JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017512679 A JP2017512679 A JP 2017512679A JP 2017526695 A5 JP2017526695 A5 JP 2017526695A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
composition according
anamorelin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526695A (ja
JP6356907B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/047435 external-priority patent/WO2016036598A1/en
Publication of JP2017526695A publication Critical patent/JP2017526695A/ja
Publication of JP2017526695A5 publication Critical patent/JP2017526695A5/ja
Priority to JP2018113592A priority Critical patent/JP6923486B2/ja
Application granted granted Critical
Publication of JP6356907B2 publication Critical patent/JP6356907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512679A 2014-09-04 2015-08-28 アナモレリンに基づく医療 Active JP6356907B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018113592A JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
US62/045,976 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018113592A Division JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療

Publications (3)

Publication Number Publication Date
JP2017526695A JP2017526695A (ja) 2017-09-14
JP2017526695A5 true JP2017526695A5 (enExample) 2017-10-26
JP6356907B2 JP6356907B2 (ja) 2018-07-11

Family

ID=55436476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512679A Active JP6356907B2 (ja) 2014-09-04 2015-08-28 アナモレリンに基づく医療
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018113592A Active JP6923486B2 (ja) 2014-09-04 2018-06-14 アナモレリンに基づく医療
JP2021029775A Active JP7044918B2 (ja) 2014-09-04 2021-02-26 アナモレリンに基づく医療

Country Status (44)

Country Link
US (5) US9675600B2 (enExample)
EP (2) EP3188599B1 (enExample)
JP (3) JP6356907B2 (enExample)
KR (3) KR101881264B1 (enExample)
CN (5) CN113577074A (enExample)
AP (1) AP2017009772A0 (enExample)
AR (1) AR103118A1 (enExample)
AU (1) AU2015312231B2 (enExample)
BR (1) BR112017003552A2 (enExample)
CA (1) CA2959158A1 (enExample)
CL (1) CL2017000494A1 (enExample)
CO (1) CO2017003263A2 (enExample)
CR (1) CR20170121A (enExample)
CY (1) CY1122746T1 (enExample)
DK (1) DK3188599T3 (enExample)
DO (1) DOP2017000055A (enExample)
EA (1) EA035578B1 (enExample)
EC (1) ECSP17019893A (enExample)
ES (1) ES2761777T3 (enExample)
GE (1) GEP20186939B (enExample)
HR (1) HRP20192345T1 (enExample)
HU (1) HUE046894T2 (enExample)
IL (1) IL250692B (enExample)
JO (1) JO3541B1 (enExample)
LT (1) LT3188599T (enExample)
MA (1) MA40607B1 (enExample)
MD (1) MD4710C1 (enExample)
ME (1) ME03597B (enExample)
MX (1) MX361741B (enExample)
MY (1) MY187167A (enExample)
NI (1) NI201700024A (enExample)
PE (1) PE20171109A1 (enExample)
PH (1) PH12017500392B1 (enExample)
PL (1) PL3188599T3 (enExample)
PT (1) PT3188599T (enExample)
RS (1) RS59751B1 (enExample)
SG (1) SG11201701567UA (enExample)
SI (1) SI3188599T1 (enExample)
SV (1) SV2017005400A (enExample)
TN (1) TN2017000040A1 (enExample)
TW (1) TWI639429B (enExample)
UA (1) UA120765C2 (enExample)
UY (1) UY36286A (enExample)
WO (1) WO2016036598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
SG11201701567UA (en) 2014-09-04 2017-03-30 Helsinn Healthcare Sa Medical treatments based on anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
EP3897681A4 (en) 2018-12-20 2022-10-26 Société des Produits Nestlé S.A. DOSING SCHEDULE APPLICABLE FOR ORAL IMMUNOTHERAPY AGAINST PEANUT FOR MISSED DOSES
JP7574222B2 (ja) 2019-05-10 2024-10-28 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ピーナツアレルギー患者の生活の質を改善するための方法
EP4021419A1 (en) 2019-08-30 2022-07-06 Helsinn Healthcare SA Methods of manufacturing anamorelin tablets having improved stability
EP4049658A4 (en) 2019-10-24 2023-11-22 Toray Industries, Inc. THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST CACHEXIA
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
CA2565324A1 (en) 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
EP1768976B1 (en) * 2004-06-29 2017-04-26 Helsinn Healthcare S.A. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
JP2010518158A (ja) * 2007-02-13 2010-05-27 ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
JP2015517452A (ja) * 2012-05-25 2015-06-22 ラクオリア創薬株式会社 無酸症を治療するためのグレリン受容体アゴニスト
SG11201701567UA (en) 2014-09-04 2017-03-30 Helsinn Healthcare Sa Medical treatments based on anamorelin

Similar Documents

Publication Publication Date Title
JP2017526695A5 (enExample)
JP2019503365A5 (enExample)
JP2015515475A5 (enExample)
FI3849534T3 (fi) Yhdistelmähoidot
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2016528162A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
JP2015505564A5 (enExample)
JP2016147915A5 (enExample)
JP2016512817A5 (enExample)
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
MY174084A (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
JP2018090566A5 (enExample)
HRP20192345T1 (hr) Medicinski tretmani na bazi anamorelina
JP2014508758A5 (enExample)
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2017526693A5 (enExample)
JP2016505050A5 (enExample)
MX2018001989A (es) Formulaciones farmaceuticas.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JP5976923B2 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same